Thrombocytopenia
Pipeline by Development Stage
Hematology is a $3.6B market dominated by a single blockbuster (IMBRUVICA at 65% share) with moderate consolidation among 15 companies.
Key Trends
- IMBRUVICA monopoly creates revenue concentration risk but sustained peak-cycle performance
- Multiple patent cliffs 2027-2030 will drive significant biosimilar/generic competition
- 1,109 active trials signal robust pipeline activity in underexplored indications like myelofibrosis and platelet disorders
Career Verdict
Hematology offers solid commercial and medical affairs opportunities in a stable, high-margin market, but pipeline diversity remains limited outside oncology-adjacent BTK inhibitors.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 65% | Peak | Stable | 9.0yr |
| 2 | PROMACTA (eltrombopag olamine) | Novartis | $558M | 15% | LOE Approaching | Declining | 1.7yr |
| 3 | AURYXIA (ferric citrate) | Ipsen | $183M | 5% | Peak | Stable | 4.2yr |
| 4 | OXBRYTA (voxelotor) | Pfizer | $101M | 3% | Peak | Growing | 11.4yr |
| 5 | DOPTELET (avatrombopag maleate) | Unknown | $96M | 3% | LOE Approaching | Declining | 1.2yr |
Drug Class Breakdown
dominates market, stable
multiple players, patent risk
niche, CKD-focused
sickle cell focused, growing
myeloproliferative neoplasms, early growth
legacy class, biosimilar pressure
biosimilar-saturated, mature
Career Outlook
StableHematology is a stable, mature therapeutic area with predictable commercial demand but limited innovation upside. The market is defensible by IMBRUVICA (peak through 2035) and near-term patent cliff risks (2027-2030) will create managed-care and payer expertise needs. Long-term career growth depends on successful pipeline diversification beyond BTK inhibitors and late-stage pipeline expansion.
Breaking In
Enter via Clinical Operations or Medical Affairs to build hematology disease knowledge; specialize early in rare indications (ITP, myelofibrosis) where differentiation exists.
For Experienced Professionals
Experienced professionals should target Bristol Myers Squibb, Novartis, or GSK to lead patent-cliff transition strategies and next-generation mechanism adoption (JAK, TPO agonists).
In-Demand Skills
Best For
Hiring Landscape
Hematology hiring is concentrated in Commercial (24 roles, $201K avg) and Medical Affairs (15 roles, $204K avg) functions, reflecting a mature market focused on market penetration and specialist education. Labcorp, Bristol Myers Squibb, and Regeneron lead hiring, suggesting demand in diagnostics, R&D, and rare disease support. Notably low R&D hiring (7 roles, $147K avg) indicates limited pipeline-driven growth outside established players.
Top Hiring Companies
By Department
Commercial and Medical Affairs roles offer highest compensation and most openings; entry-level clinical operations salaries lag at $91K, while R&D roles are scarce and lower-paid.
Competitive Landscape
16 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 21 trials with date data
Clinical Trials (21)
Total enrollment: 1,615 patients across 21 trials
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Prospective Study of Patients With Thrombocytopenia Following HSCT
Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
Strategies for Transfusion of Platelets (SToP)
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
Study of Eltrombopag in Platelet Refractory Thrombocytopenia
A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients
Thrombosomes® in Bleeding Thrombocytopenic Patients
A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects
Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State
Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State
The International ITP Registry
The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC
Stem Cell Transplantation (SCT) for Genetic Diseases
Related Jobs in Hematology
Account Operations Manager - Southeast
Manager, Global Regulatory Operations
Associate Director of Strategic Accounts, Hematology – Great Lakes
Quality Assurance Specialist
Director, Contracts Counsel
SALES REP SR - Hematologia (São Paulo)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.